Dr. David R. Wise, MD, PhD

Dr. Wise practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Wise's NPI, 1336438258, was assigned on March 31, 2011. Dr. Wise graduated from Perelman School of Medicine at the University of Pennsylvania in 2011. Dr. Wise holds New York license 270704.

Dr. Wise's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Wise's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Wise is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Wise to 2 more home health agencies and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wise practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Wise's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Wise is licensed in New York.

CMS data shows 894 Medicare services from Dr. Wise across 7 procedure codes in 2024, for 335 Medicare patients. Medicare paid $80,334 for them. Every service was in an office.

CMS counts 335 Medicare patients who saw Dr. Wise in 2024. The largest group is 75 to 84, with 163 patients. 75% of them have cancer, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wise's median patient age at 75, with 2% women.

In 2024, Dr. Wise wrote 1,219 Medicare Part D claims for 182 patients. 58% of them were for generic drugs. CMS names the drug for 1,087 of them, across 15 drugs with 11 or more claims each, at $5,207,668 in total drug cost. In 2023, CMS named 465 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Wise for performance year 2024, reported as part of a group. Dr. Wise accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wise as offering telehealth.

Dmand AI links 30 papers to Dr. Wise, published from 2011 to 2025. 2025 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Genetic Testing and Germ-Line Mutation. Dr. Wise has published most often in Eur Radiol. Dr. Wise's most frequent co-authors are Christopher M. Pieczonka, MD, Anton Sebastian Becker, MD, PhD and Minas Platon Economides, MD.

Dmand AI links Dr. Wise to 7 clinical trials, 2 of them phase 1/2 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Wise that name 3 trials.

CMS Open Payments shows 51 general payments to Dr. Wise from 10 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 88% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $20,918. It also lists 11 research payments totaling $3,834 from 2018 to 2025, naming 3 clinical trials.

Dr. Wise graduated from Perelman School of Medicine at the University of Pennsylvania in 2011.